NEW YORK (GenomeWeb) – German molecular diagnostics firm Curetis has successfully completed a large clinical trial of its lower respiratory panel (LRP) in anticipation of submitting the panel and its Unyvero system to the US Food and Drug Administration by the end of the year.

The panel is designed for critical lower respiratory tract infections, which are often diagnosed as pneumonia, and detects 21 different pathogens and 19 resistance markers, Curetis' CEO Oliver Schacht told GenomeWeb in an interview. It is currently CE-marked in Europe, where it is known as a pneumonia panel.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In this webinar, Jill Viles, an Iowa mother with no clinical training, shares her story of how she self-diagnosed her rare condition, a muscle-wasting disease caused by a mutation in the LMNA gene. She will also discuss how she discovered that a mutation in the same gene is the underlying cause for the excess muscle phenotype exhibited by Canadian Olympic hurdler Priscilla Lopes-Schliep.